Clinical Utility of Mac-2 Binding Protein Glycosylation Isomer in Chronic Liver Diseases

키워드

참고문헌 (105)

1. Dienstag JL, "The role of liver biopsy in chronic hepatitis C", Hepatology, 36(S1), pp.S152~S160 (2002)
2. Gebo KA, "Role of liver biopsy in management of chronic hepatitis C: a systematic review", Hepatology, 36(S1), pp.S161~S172 (2002)
3. Yin M, "Assessment of hepatic fibrosis with magnetic resonance elastography", Clin Gastroenterol Hepatol, 5, pp.1207~1213.e2 (2007)
4. Loomba R, "Magnetic resonance elastography predicts advanced fibrosis in patients with nonalcoholic fatty liver disease: a prospective study", Hepatology, 60, pp.1920~1928 (2014)
5. Tamaki N, "Risk assessment of hepatocellular carcinoma development by magnetic resonance elastography in chronic hepatitis C patients who achieved sustained virological responses by direct-acting antivirals", J Viral Hepat, 26, pp.893~899 (2019)
6. Higuchi M, "Prediction of hepatocellular carcinoma after sustained virological responses using magnetic resonance elastography", Clin Gastroenterol Hepatol, 17, pp.2616~2618 (2009)
7. Castera L, "Non-invasive evaluation of liver fibrosis using transient elastography", J Hepatol, 48, pp.835~847 (2008)
8. Tamaki N, "Prospective comparison of real-time tissue elastography and serum fibrosis markers for the estimation of liver fibrosis in chronic hepatitis C patients", Hepatol Res, 44, pp.720~727 (2014)
9. Yada N, "Diagnosis of fibrosis and activity by a combined use of strain and shear wave imaging in patients with liver disease", Dig Dis, 35, pp.515~520 (2017)
10. Loomba R, "Advances in non-invasive assessment of hepatic fibrosis", Gut, 69, pp.1343~1352 (2020)
11. Ajmera VH, "Clinical utility of an increase in magnetic resonance elastography in predicting fibrosis progression in nonalcoholic fatty liver disease", Hepatology, 71, pp.849~860 (2020)
12. Loomba R, "Multicenter validation of association between decline in MRI-PDFF and histologic response in nonalcoholic steatohepatitis", Hepatology, 21, pp.31121~ (2020)
13. Tamaki N, "Novel quantitative assessment system of liver steatosis using a newly developed attenuation measurement method", Hepatol Res, 48, pp.821~828 (2018)
14. Sterling RK, "Development of a simple noninvasive index to predict significant fibrosis in patients with HIV", HCV coinfection, 2006, pp.43, 1317~1325
15. Tamaki N, "Noninvasive estimation of fibrosis progression overtime using the FIB4 index in chronic hepatitis C", J Viral Hepat, 20, pp.72~76 (2013)
16. Tamaki N, "Non-invasive prediction of hepatocellular carcinoma development using serum fibrosis marker in chronic hepatitis C patients", J Gastroenterol, 49, pp.1495~1503 (2014)
17. Takahashi Y, "Non-alcoholic fatty liver disease fibrosis score and FIB-4 scoring system could identify patients at risk of systemic complications", Hepatol Res, 45, pp.667~675 (2015)
18. Castera L, "Noninvasive assessment of liver disease in patients with nonalcoholic fatty liver disease", Gastroenterology, 156, pp.1264~1281.e4 (2019)
19. Kuno A, "A serum “sweet-doughnut” protein facilitates fibrosis evaluation and therapy assessment in patients with viral hepatitis", Sci Rep, 3, pp.1065~ (2013)
20. Shirabe K, "Mac-2binding protein glycan isomer (M2BPGi) is a new serum biomarker for assessing liver fibrosis: more than a biomarker of liver fibrosis", J Gastroenterol, 53, pp.819~826 (2018)
21. Ito K, "Serum Wisteria floribunda agglutinin-positive Mac-2-binding protein levels and liver fibrosis: a meta-analysis", J Gastroenterol Hepatol, 32, pp.1922~1930 (2017)
22. 문희원, "Usefulness of Enhanced Liver Fibrosis, Glycosylation Isomer of Mac-2 Binding Protein, Galectin-3, and Soluble Suppression of Tumorigenicity 2 for Assessing Liver Fibrosis in Chronic Liver Diseases", Annals of Laboratory Medicine, 38(4), pp.331~337 (2018), 대한진단검사의학회
23. Toshima T, "A novel serum marker, glycosylated Wisteria floribunda agglutinin-positive Mac-2 binding protein (WFA(+)-M2BP), for assessing liver fibrosis", J Gastroenterol, 50, pp.76~84 (2015)
24. Baudi I, "Novel biomarkers of hepatitis B and hepatocellular carcinoma: clinical significance of HBcrAg and M2BPGi", Int J Mol Sci, 21, pp.949~ (2020)
25. Yoneda M, "Clinical strategy of diagnosing and following patients with nonalcoholic fatty liver disease based on invasive and noninvasive methods", J Gastroenterol, 53, pp.181~196 (2018)
26. Yasui Y, "Non-invasive liver fibrosis assessment correlates with collagen and elastic fiber quantity in patients with hepatitis C virus infection", Hepatol Res, 49, pp.33~41 (2019)
27. Rosenberg I, "Mac-2-binding glycoproteins. Putative ligands for a cytosolic beta-galactoside lectin", J Biol Chem, 266, pp.18731~18736 (1991)
28. Narimatsu H, "Development of M2BPGi: a novel fibrosis serum glycobiomarker for chronic hepatitis", cirrhosis diagnostics, 2015, pp.12, 683~693
29. Kuno A, "Reconstruction of a robust glycodiagnostic agent supported by multiple lectin-assisted glycan profiling", Proteomics Clin Appl, 7, pp.642~647 (2013)
30. Bekki Y, "Hepatic stellate cells secreting WFA+-M2BP: its role in biological interactions with Kupffer cells", J Gastroenterol Hepatol, 32, pp.1387~1393 (2017)
31. Yamasaki K, "Elevated serum levels of Wisteria floribunda agglutinin-positive human Mac-2 binding protein predict the development of hepatocellular carcinoma in hepatitis C patients", Hepatology, 60, pp.1563~1570 (2014)
32. Tamaki N, "Wisteria floribunda agglutinin positive human Mac-2-binding protein as a predictor of hepatocellular carcinoma development in chronic hepatitis C patients", Hepatol Res, 45, pp.E82~E88 (2015)
33. Ura K, "Serum WFA(+) -M2BP is a non-invasive liver fibrosis marker that can predict the efficacy of direct-acting anti-viral-based triple therapy for chronic hepatitis C", Aliment Pharmacol Ther, 43, pp.114~124 (2016)
34. Huang CI, "Serum Wisteria floribunda agglutinin-positive Mac-2-binding protein expression predicts disease severity in chronic hepatitis C patients", Kaohsiung J Med Sci, 33, pp.394~399 (2017)
35. Fujita K, "Fibrosis staging using direct serum biomarkers is influenced by hepatitis activity grading in hepatitis C virus infection", J Clin Med, 7, pp.267~ (2018)
36. Inoue T, "Clinical evaluation of hepatocarcinogenesis and outcome using a novel glycobiomarker Wisteria floribunda agglutinin-positive Mac-2 binding protein (WFA+-M2BP) in chronic hepatitis C with advanced fibrosis", Jpn J Infect Dis, 71, pp.177~183 (2018)
37. Nakamura M, "Serum microRNA-122 and Wisteria floribunda agglutinin-positive Mac-2binding protein are useful tools for liquid biopsy of the patients with hep-atitis B virus and advanced liver fibrosis", PLoS One, 12, pp.e0177302~ (2017)
38. Xu H, "Accuracy of M2BPGi, compared with Fibro Scan®, in analysis of liver fibrosis in patients with hepatitis C", BMC Gastroenterol, 17, pp.62~ (2017)
39. Lin YJ, "A glycomarker for short-term prediction of hepatocellular carcinoma: a longitudinal study with serial measurements", Clin Transl Gastroenterol, 9, pp.183~ (2018)
40. Tsuji K, "Realworld efficacy and safety of ledipasvir and sofosbuvir in patients with hepatitis C virus genotype 1 infection: a nationwide multicenter study by the Japanese Red Cross Liver Study Group", J Gastroenterol, 53, pp.1142~1150 (2018)
41. Izumi N, "Sofosbuvir-velpatasvir plus ribavirin in Japanese patients with genotype 1 or 2 hepatitis C who failed direct-acting antivirals", Hepatol Int, 12, pp.356~367 (2018)
42. Fujii H, "Efficacy of daclatasvir plus asunaprevir in patients with hepatitis C virus infection undergoing and not undergoing hemodialysis", Hepatol Res, 48, pp.746~756 (2018)
43. Akahane T, "Real-world efficacy and safety of sofosbuvir + ribavirin for hepatitis C genotype 2: A nationwide multicenter study by the Japanese Red Cross Liver Study Group", Hepatol Res, 49, pp.264~270 (2019)
44. Sato S, "Prediction of hepatocellular carcinoma development after hepatitis C virus eradication using serum Wisteria floribunda agglutinin-positive Mac2-Binding protein", Int J Mol Sci, 17, pp.2143~ (2016)
45. Nagata H, "Serial measurement of Wisteria floribunda agglutinin positive Mac-2-binding protein is useful for predicting liver fibrosis and the development of hepatocellular carcinoma in chronic hepatitis C patients treated with IFN-based and IFN-free therapy", Hepatol Int, 10, pp.956~964 (2016)
46. Miyaki E, "Daclatasvir and asunaprevir treatment improves liver function parameters and reduces liver fibrosis markers in chronic hepatitis C patients", Hepatol Res, 46, pp.758~764 (2016)
47. Morio K, "Wisteria floribunda agglutinin positive Mac-2-binding protein level increases in patients with acute liver injury", J Gastroenterol, 52, pp.1252~1257 (2017)
48. Sasaki R, "Serum Wisteria floribunda agglutinin-positive Mac-2 binding protein values predict the development of hepatocellular carcinoma among patients with chronic hepatitis C after sustained virological response", PLoS One, 10, pp.e0129053~ (2015)
49. Nagata H, "Effect of interferon-based and -free therapy on early occurrence and recurrence of hepatocellular carcinoma in chronic hepatitis C", J Hepatol, 67, pp.933~939 (2017)
50. Yasui Y, "Wisteria floribunda agglutinin-positive Mac-2 binding protein predicts early occurrence of hepatocellular carcinoma after sustained virologic response by direct-acting antivirals for hepatitis C virus", Hepatol Res, 48, pp.1131~1139 (2018)
51. Akuta N, "Complex association of virus- and host-related factors with hepatocellular carcinoma rate following hepatitis C virus clearance", J Clin Microbiol, 57, pp.01463-18~ (2019)
52. Ishii A, "Clinical implications of serum Wisteria floribunda agglutinin-positive Mac-2-binding protein in treatment-naive chronic hepatitis B", Hepatol Res, 47, pp.204~215 (2017)
53. Ichikawa Y, "Serum Wisteria floribunda agglutinin-positive human Mac-2 binding protein may predict liver fibrosis and progression to hepatocellular carcinoma in patients with chronic hepatitis B virus infection", Hepatol Res, 47, pp.226~233 (2017)
54. Yeh ML, "Wisteria floribunda agglutinin-positive Mac-2-binding protein in the prediction of disease severity in chronic hepatitis B patients", PLoS One, 14, pp.e0220663~ (2019)
55. Dong Wook Jekarl, "Diagnosis of Liver Fibrosis With Wisteria floribunda Agglutinin-Positive Mac-2 Binding Protein (WFAM2BP) Among Chronic Hepatitis B Patients", Annals of Laboratory Medicine, 38(4), pp.348~354 (2018), 대한진단검사의학회
56. Mak LY, "Role of serum M2BPGi levels on diagnosing significant liver fibrosis and cirrhosis in treated patients with chronic hepatitis B virus infection", Clin Transl Gastroenterol, 9, pp.163~ (2018)
57. Wei B, "M2BPGi as a potential diagnostic tool of cirrhosis in Chinese patients with hepatitis B virus infection", J Clin Lab Anal, 32, pp.24~ (2018)
58. Jun T, "Mac-2binding protein glycosylation isomer as a hepatocellular carcinoma marker in patients with chronic hepatitis B or C infection", Hepatol Commun, 3, pp.493~503 (2019)
59. Nishikawa H, "Serum Wisteria floribunda agglutinin-positive Mac-2-binding protein for patients with chronic hepatitis B and C: a comparative study", J Viral Hepat, 23, pp.977~984 (2016)
60. Chuaypen N, "Serum Wisteria floribunda agglutinin-positive Mac-2 binding protein level as a diagnostic marker of hepatitis B virusrelated hepatocellular carcinoma", Hepatol Res, 48, pp.872~881 (2018)
61. Cheung KS, "Wisteria floribunda agglutinin-positive human Mac-2 binding protein predicts liver cancer development in chronic hepatitis B patients under antiviral treatment", Oncotarget, 8, pp.47507~47517 (2017)
62. Liu J, "Serum levels of M2BPGi as short-term predictors of hepatocellular carcinoma in untreated chronic hepatitis B patients", Sci Rep, 7, pp.14352~ (2017)
63. Kim SU, "Wisteria floribunda agglutinin-positive human Mac-2 binding protein predicts the risk of HBV-related liver cancer development", Liver Int, 37, pp.879~887 (2017)
64. Mak LY, "Serum Mac-2-binding protein glycosylation isomer and risk of hepatocellular carcinoma in entecavir-treated chronic hepatitis B patients", J Gastroenterol Hepatol, 34, pp.1817~1823 (2019)
65. Kawaguchi K, "Serum Wisteria floribunda agglutinin-positive Mac-2 binding protein predicts hepatocellular carcinoma incidence and recurrence in nucleos(t)ide analogue therapy for chronic hepatitis B", J Gastroenterol, 53, pp.740~751 (2018)
66. Shinkai N, "High levels of serum Mac-2-binding protein glycosylation isomer (M2BPGi) predict the development of hepatocellular carcinoma in hep atitis B patients treated with nucleot(s)ide analogues", J Gastroenterol, 53, pp.883~889 (2018)
67. Su TH, "Serum Mac2-Binding protein glycosylation isomer at virological remission predicts hepatocellular carcinoma and death in chronic hepatitis B-related cirrhosis", J Infect Dis, 221, pp.589~597 (2020)
68. Heo JY, "Use of Wisteria floribunda agglutinin-positive human Mac-2 binding protein in assessing risk of hepatocellular carcinoma due to hepatitis B virus", Medicine (Baltimore), 95, pp.e3328~ (2016)
69. Mak LY, "Serum Mac-2binding protein glycosylation isomer level predicts hepatocellular carcinoma development in E-negative chronic hepatitis B patients", World J Gastroenterol, 25, pp.1398~1408 (2019)
70. Hsu YC, "Serum M2BPGi level and risk of hepatocellular carcinoma after oral anti-viral therapy in patients with chronic hepatitis B", Aliment Pharmacol Ther, 48, pp.1128~1137 (2018)
71. Abe M, "Association between Wisteria floribunda agglutinin-positive Mac-2 binding protein and the fibrosis stage of non-alcoholic fatty liver disease", J Gastroenterol, 50, pp.776~784 (2015)
72. Ogawa Y, "Wisteria floribunda agglutinin-positive Mac-2-binding protein and type 4 collagen 7S: useful markers for the diagnosis of significant fibrosis in patients with non-alcoholic fatty liver disease", J Gastroenterol Hepatol, 33, pp.1795~1803 (2018)
73. Nishikawa H, "Clinical significance of serum Wisteria floribunda agglutinin positive Mac-2-binding protein level in non-alcoholic steatohepatitis", Hepatol Res, 46, pp.1194~1202 (2016)
74. Atsukawa M, "Serum Wisteria floribunda agglutinin-positive Mac-2 binding protein more reliably distinguishes liver fibrosis stages in non-alcoholic fatty liver disease than serum Mac-2 binding protein", Hepatol Res, 48, pp.424~432 (2018)
75. Alkhouri N, "Serum Wisteria floribunda agglutinin-positive Mac-2-binding protein levels predict the presence of fibrotic nonalcoholic steatohepatitis (NASH)and NASH cirrhosis", PLoS One, 13, pp.e0202226~ (2018)
76. Shigefuku R, "Correlations of hepatic hemodynamics, liver function, and fibrosis markers in nonalcoholic fatty liver disease: comparison with chronic hepatitis related to hepatitis C virus", Int J Mol Sci, 17, pp.1545~ (2016)
77. Ishiba H, "The novel cutoff points for the FIB4 index categorized by age increase the diagnostic accuracy in NAFLD: a multi-center study", J Gastroenterol, 53, pp.1216~1224 (2018)
78. Tamaki N, "Wisteria floribunda agglutinin-positive mac-2 binding protein as an age-independent fibrosis marker in nonalcoholic fatty liver disease", Sci Rep, 9, pp.10109~ (2019)
79. Kawanaka M, "Wisteria floribunda agglutinin-positive Mac-2 binding protein predicts the development of hepatocellular carcinoma in patients with nonalcoholic fatty liver disease", Hepatol Res, 48, pp.521~528 (2018)
80. Kanno M, "Serum aldo-keto reductase family 1 member B10 predicts advanced liver fibrosis and fatal complications of nonalcoholic steatohepatitis", J Gastroenterol, 54, pp.549~557 (2019)
81. Nah EH, "Diagnostic performance of Mac-2 binding protein glycosylation isomer (M2BPGi) in screening liver fibrosis in health checkups", J Clin Lab Anal, pp.e23316~ (2020)
82. Hanai T, "Impact of serum glycosylated Wisteria floribunda agglutinin positive Mac2 binding protein levels on liver functional reserves and mortality in patients with liver cirrhosis", Hepatol Res, 45, pp.1083~1090 (2015)
83. Uojima H, "Wisteria floribunda agglutinin-positive human Mac-2 binding protein in decompensated cirrhosis", J Gastroenterol Hepatol, 33, pp.1889~1896 (2018)
84. Xu WP, "Serum Wisteria floribunda agglutinin-positive Mac-2-binding protein evaluates liver function and predicts prognosis in liver cirrhosis", J Dig Dis, 19, pp.242~253 (2018)
85. Hayashi T, "Use of the serum Wisteria floribunda agglutinin-positive Mac2 binding protein as a marker of gastroesophageal varices and liver-related events in chronic hepatitis C patients", Diagnostics (Basel), 10, pp.173~ (2020)
86. Lin J, "Prognostic role of serum Wisteria floribunda agglutinin-positive Mac-2 binding protein level in early stage hepatocellular carcinoma", Sci Rep, 10, pp.5651~ (2020)
87. Imai D, "Elevation of Mac-2 binding protein glycosylation isomer after hepatectomy is associated with post-hepatectomy liver failure, total Pringle time, and renal dysfunction", Ann Gastroenterol Surg, 3, pp.515~522 (2019)
88. Ishii N, "Preoperative Mac-2 binding protein glycosylation isomer level predicts postoperative ascites in patients with hepatic resection for hepatocellular carcinoma", Hepatol Res, 49, pp.1398~1405 (2019)
89. Okuda Y, "Usefulness of Mac-2 binding protein glycosylation isomer for prediction of posthepatectomy liver failure in patients with hepatocellular carcinoma", Ann Surg, 265, pp.1201~1208 (2017)
90. Eso Y, "Combination of Mac-2 binding protein glycosylation isomer and Up-To-seven criteria as a useful predictor for child-Pugh grade deterioration after transarterial chemoembolization for hepatocellular carcinoma", Cancers (Basel), 11, pp.405~ (2019)
91. Totani H, "The value of serum Wisteria floribunda agglutinin-positive human Mac-2-binding protein as a predictive marker for hepatitis C virus-related complications after systemic chemotherapy", Int J Hematol, 104, pp.384~391 (2016)
92. Fujiyoshi M, "Clinicopathological characteristics and diagnostic performance of Wisteria floribunda agglutinin positive Mac-2-binding protein as a preoperative serum marker of liver fibrosis in hepatocellular carcinoma", J Gastroenterol, 50, pp.1134~1144 (2015)
93. Toyoda H, "Serum WFA+-M2BP levels as a prognostic factor in patients with early hepatocellular carcinoma undergoing curative resection", Liver Int, 36, pp.293~301 (2016)
94. Hye Soo Kim, "Serum Wisteria floribunda agglutinin-positive human Mac-2 binding protein level predicts recurrence of hepatitis B virus-related hepatocellular carcinoma after curative resection", Clinical and Molecular Hepatology, 26(1), pp.33~44 (2020), 대한간학회
95. Sung JH, "Risk factors for loss of skeletal muscle mass in patients with cirrhosis", Hep-atol Res, 49, pp.550~558 (2019)
96. Nishikawa H, "Significant correlation between grip strength and m2bpgi in patients with chronic liver Diseases", J Clin Med, 8, pp.1359~ (2019)
97. Nishikawa H, "Clinical significance of serum Wisteria floribunda agglutinin positive Mac-2-binding protein level and high-sensitivity C-reactive protein concentration in autoimmune hepatitis", Hepatol Res, 46, pp.613~621 (2016)
98. Migita K, "Serum cytokine profiles and Mac-2 binding protein glycosylation isomer (M2-BPGi) level in patients with autoimmune hepatitis", Medicine (Baltimore), 97, pp.e13450~ (2018)
99. Umemura T, "Serum Wisteria floribunda agglutinin-positive Mac-2-binding protein level predicts liver fibrosis and prognosis in primary biliary cirrhosis", Am J Gastroenterol, 110, pp.857~864 (2015)
100. Nishikawa H, "Impact of serum Wisteria floribunda agglutinin positive Mac-2-binding protein and serum interferon-gamma-inducible protein-10 in primary biliary cirrhosis", Hepatol Res, 46, pp.575~583 (2016)
101. Ueno T, "Clinical implications of serum Mac-2-binding protein (M2BPGi) during regular follow-up of patients with biliary atresia", Pediatr Surg Int, 34, pp.1065~1071 (2018)
102. Yamada N, "Serum Mac-2 binding protein glycosylation isomer predicts the activation of hepatic stellate cells after liver transplantation", J Gastroenterol Hepatol, 34, pp.418~424 (2019)
103. Umetsu S, "Usefulness of serum Wisteria floribunda agglutinin-positive Mac-2 binding protein in children with primary sclerosing cholangitis", Hepatol Res, 48, pp.355~363 (2018)
104. Osawa L, "Wisteria floribunda agglutinin-positive Mac-2 binding protein but not α-fetoprotein as a long-term hepatocellular carcinoma predictor", Int J Mol Sci, 21, pp.3640~ (2020)
105. Uchiyama H, "Peritransplant kinetics of Mac-2-binding protein glycosylation isomer levels in living donor liver transplantation: its implication of posttransplant small-for-size syndrome", Transl Gastroenterol Hepatol, 4, pp.41~ (2019)

관련 논문AI추천